Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
By Colin Kellaher
Moderna on Friday said the Food and Drug Administration won't meet its May 12 target action date for a decision on the company's proposed vaccine for respiratory syncytial virus, or RSV, but that the agency hasn't flagged any issues that would prevent an approval.
The company said the FDA cited administrative constraints for the delay, and that the agency is working to complete its review of mRNA-1345 by the end of the month.
Moderna said the FDA hasn't informed the Cambridge, Mass., vaccine maker of any issues related to vaccine safety, efficacy or quality that would prevent the approval of mRNA-1345 for RSV, a contagious virus that is the leading cause of respiratory illness in young children and also poses increased risk to older adults for severe outcomes.
Moderna has previously said it estimates the peak annual RSV market to be about $10 billion, and that it expects a strong RSV vaccine launch this year.
The company also said it remains on track for mRNA-1345 to be reviewed at the Centers for Disease Control and Prevention's advisory committee on immunization practices in late June, which is necessary prior to commercial launch.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 10, 2024 07:48 ET (11:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now